AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03546335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 89Zr-DFO-CZP
Description: 89Zr-DFO-Certolizumab pegol (89Zr-DFO-CZP) is a radiopharmaceutical imaging agent that will be produced under Current Good Manufacturing Practice (CGMP) regulations in the Department of Radiology and Biomedical Imaging Radiopharmaceutical Facility at University of California, San Francisco (UCSF).
Study NCT04104321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aramchol free acid
Description: Aramchol 300 mg BID
Study NCT04104321 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo BID
Study NCT05189769 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CP no REACT
Description: Coping Power no REACT
Study NCT05189769 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CP+/No REACT
Description: CP+ and no REACT
Study NCT05189769 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CP and REACT
Description: Coping Power traditional and REACT
Study NCT05189769 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CP+ and REACT
Description: CP+ and REACT
Study NCT01171352 — intervention group
Intervention type: PROCEDURE
Intervention: Transpulmonary Thermodilution
Description: A PiCCO femoral catheter will be placed and PiCCO parameters will be obtained using transpulmonary thermodilution after continuous dialysis is ordered or just prior to initiation of intermittent dialysis, hourly until either completion of intermittent dialysis or 8 hours of continuous dialysis is completed.
Study NCT02087748 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1% diclofenac sodium gel
Description: Diclofenac sodium 1% gel 4 grams applied topically Q6 hour for 48 hours
Study NCT02087748 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo gel 4gm applied topically Q6 hour for 48 hours
Study NCT00955487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Nitric Oxide (iNO)
Description: iNO will be delivered using the iNOVent device to provide 10 ppm proximally (yielding approximately 5 ppm to the posterior pharynx).
Study NCT00955487 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nitrogen (placebo)
Description: Nitrogen will be delivered using the iNOVent device to provide 10 ppm proximally (yielding approximately 5 ppm to the posterior pharynx).
Study NCT01310803 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VALSTAR - Maintenance Therapy
Description: Treatment phase - 10 monthly intravesical installations starting 10 to 12 weeks after the beginning of induction. Follow-up phase
Study NCT01310803 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No Maintenance treatment ( Standard of Care)
Description: Subjects randomized to No Maintenance (Standard of Care) will not receive any additional intravesical therapy
Study NCT00584168 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: They will take a pill the day before surgery, twice daily for the next four days and then once daily for the next two days for a total of seven days.
Study NCT00584168 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: They will take a pill the day before surgery, twice daily for the next four days and then once daily for the next two days for a total of seven days.
Study NCT03047551 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transabdominal sonography
Description: Ultrasound machines vary by site. At Planned Parenthood and Columbia University Medical Center, providers utilize the LOGIQ P5 ultrasound machine, manufactured by General Electric Healthcare.
Study NCT03047551 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transvaginal sonography
Description: Ultrasound machines vary by site. At Planned Parenthood and Columbia University Medical Center, providers utilize the LOGIQ P5 ultrasound machine, manufactured by General Electric Healthcare.
Study NCT01641211 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meducation device technique video
Description: 2-minute video that displays proper inhaler, diskus, and turbuhaler technique. The video will only be watched once at the medical visit. Children in this group will be given a wallet card so they can access the video via the Internet after leaving the asthma clinic.
Study NCT01641211 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Nutrition video
Description: Children in this group will watch a 2-minute nutrition video.
Study NCT02462928 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abicipar Pegol
Description: Abicipar pegol intravitreal injection.
Study NCT02462928 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: Ranibizumab intravitreal injection.
Study NCT02462928 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sham Procedure
Description: Sham injection.
Study NCT01135680 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HPN-100
Description: single oral dose of 9 mL HPN-100 given via syringes 3 times daily for 3 days
Study NCT01135680 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HPN-100 or Placebo
Description: single oral dose of 12 mL HPN-100 given via syringes 3 times daily for 3 days
Study NCT01135680 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: single oral (by mouth) dose of 9 mL placebo given via syringes 3 times daily for 3 days
Study NCT01135680 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Moxifloxacin
Description: single oral 400-mg dose on study Day 3
Study NCT01135680 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HPN-100
Description: single oral dose of 6 mL HPN-100 and 3 mL placebo given via syringes 3 times daily for 3 days
Study NCT02640820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sensitizing DPCP Ointment
Description: Sensitization
Study NCT02640820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment DPCP Ointment
Description: Treatment
Study NCT00643669 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL-3789 Sterile Suspension
Description: Single administration by anterior juxtascleral depot
Study NCT00146328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tipranavir
Study NCT01556035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Patient orally treated with lenalidomide 25 mg daily for 21 days with 7 days rest of a 28 days cycle.Treatment maintained for 12 months unless progression
Study NCT04536584 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personalized Coaching (Arm A)
Description: Patients will receive personalized physical activity coaching with an online digital platform to take online educational workshops and interact with other peers of the cohort with a online private forum. They will also have a connected watch that will measure several physical activity metrics.
Study NCT04536584 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard supportive approach (Arm B)
Description: Patients will receive the standard recommendations during their visits with the oncologist. The exercise recommendations include strength training and aerobic activities.
Study NCT03434353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inarigivir Soproxil
Description: Administered orally once daily one hour before or one hour after a meal
Study NCT03434353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAF
Description: Administered orally once daily with food
Study NCT03739762 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: i-STAND
Description: Via in-person and phone coaching sessions, participants randomized to this arm will be coached to find ways to sit less and stand more, and look for ways to change their home environment to encourage this, as well as look at how their lifestyle may contribute to their sitting time. Participants in this arm may be re-randomized at the half-way point to continue with additional phone coaching sessions. (As of 3/31/2022 Re-randomizations are no longer taking place)
Study NCT03739762 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Living control
Description: In this arm, participants will have phone coaching sessions focused on a variety of topics aimed at improving healthy habits. There is no focus on standing more or sitting less.
Study NCT04144751 — intervention group
Intervention type: OTHER
Intervention: Blood Sample Collection
Description: Subjects participating in the study will have blood drawn at enrollment.
Study NCT04431050 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Point of care testing of respiratory viruses.
Description: Single use point of care diagnostic device.
Study NCT00148954 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VITALITY 2 Implantable Cardioverter Defibrillator
Description: VITALITY 2 ICD
Study NCT00148954 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Medtronic Implantable Cardioverter Defibrillator
Description: Maximo, Marquis, Intrinsic, Virtuoso, or Entrust ICD
Study NCT04058379 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: CT scan
Description: 3 ct scans : D0, D1 and D3
Study NCT04292002 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Test@Work
Description: Offer of a general health check including opt-in sexual health consultation and HIV testing, weight/height, Body Mass Index (BMI), blood pressure, mental health screen. Provision of tailored health advice and a resource pack with information and signposting.
Study NCT00707850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEGASYS® (Peginterferon Alfa-2a (40KD)) Plus COPEGUS® (Ribavirin)
Description: PEGASYS: 180 microgram per week (Injection) Plus Ribavirin: \[=\<75 kg: 1000 mg; >75 kg: 1200 mg per day (PO)\]
Study NCT04469166 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: tourniquet
Description: Use of tourniquet
Study NCT04469166 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: No tourniquet
Description: No use of tourniquet
Study NCT02597803 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RGN-259
Description: A preservative-free, sterile eye drop solution containing Tβ4 for direct instillation into each eye, four times a day (QID) for 28 days
Study NCT02597803 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: It is composed of the same excipients as RGN-259 but does not contain Tβ4
Study NCT02581293 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Group 1: Only visceral peritoneum will be closed
Study NCT02581293 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Group 2 : Only parietal peritoneum will be closed
Study NCT02581293 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Group 3 : Both of them will be closed
Study NCT02581293 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Group 4: None of them will be closed
Study NCT04426955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: IV infusion
Study NCT04426955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: IV infusion
Study NCT04426955 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Description: IV infusion
Study NCT04426955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: IV infusion
Study NCT04426955 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cisplatin
Description: IV infusion
Study NCT04426955 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV infusion
Study NCT04426955 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Concurrent Radiation
Study NCT04426955 — intervention group
Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Radiation
Description: Concurrent Radiation
Study NCT04849182 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vertistop D
Description: Food supplement containing alpha-lipoic acid, carnosine, zinc, vitamin D3 and vitamins of group B, 1 tablet/day before meals
Study NCT04849182 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vertistop L
Description: Food supplement containing alpha-lipoic acid, carnosine, zinc and curcumin, 2 tablets/day (morning and evening)
Study NCT02679950 — intervention group
Intervention type: GENETIC
Intervention: Next generation genome sequencing
Description: DNA will be extracted from each sample and assayed.
Study NCT02718599 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: terlipressin
Description: Terlipressin will be started at the beginning of surgery as an initial bolus dose of 1 mg over 30 mints(1 mg/50 ml normal saline at a rate of 100 ml/h) followed by a continuous infusion of 2 μg/kg/h(1 mg/50 ml at a rate equal to wt/10 ml per hour) and weaned in the postoperative period over 4 hours.
Study NCT02718599 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: Patients receive 50 ml normal saline at a rate of 100 ml/h followed by a continuous infusion of 50 ml at a rate equal to wt/10 ml per hour and weaned in the postoperative period over 4 hours.
Study NCT02125305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Study NCT02507622 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: measurement of the concentration of C02, CO and NH4, 3 exhaled gas with E-Nose system
Study NCT02507622 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Parabolic flight
Study NCT01956825 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: slim water
Study NCT00343616 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cognitive assessment
Description: Cognitive function will be assessed using the CogState battery and the Cognitive Failures Questionnaire.
Study NCT00343616 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: fatigue assessment and management
Description: Fatigue will be evaluated using the Brief Fatigue Inventory.
Study NCT00343616 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: psychologic distress
Description: Psychologic distress will be evaluated using the General Health Questionnaire after cognitive testing.
Study NCT00343616 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Quality of life will be assessed using global linear analogue self-assessment (LASA) indicators for physical well-being, mood, coping effort (PACIS), perceived social support and subjective health estimation.
Study NCT00170612 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumovax 23
Description: 23-valent PPS, 25 micrograms/serotype
Study NCT00170612 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pneumovax 23
Description: 23-valent PPS, 25 micrograms/serotype
Study NCT00170612 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prevnar
Description: 7-valent PCV, 2 micrograms/serotype, except serotype 6B which is 4 micrograms/serotype
Study NCT01798992 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carvedilol
Study NCT01798992 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoprolol succinate
Study NCT01798992 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoprolol succinate + doxazosin
Study NCT00495404 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Physician Treatment Guidelines
Study NCT02461030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: In-office and at home Colgate sensitive pro-relief - CSPR
Description: Prophylaxis with rubber cup using In-office Colgate sensitive pro-relief (CSPR), after non-surgical periodontal therapy, and tooth brushing with at home CSPR toothpaste.
Study NCT02461030 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: In-office Villevie® prophy paste + Colgate Toothpaste
Description: Prophylaxis with rubber cup using In-office Villevie® (fluoride-free) prophy paste + Colgate Toothpaste, after non-surgical periodontal therapy.
Study NCT02461030 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-surgical periodontal treatment
Description: Full-mouth debridment, scaling and root planing with ultrasonic/hand instruments
Study NCT02461030 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Non-surgical periodontal treatment
Description: Full-mouth debridment, scaling and root planing with ultrasonic/hand instruments
Study NCT01480284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK548470 300 mg tablet
Description: Blue tablets, each tablet containing 300 mg of tenofovir disoproxil fumarate
Study NCT01480284 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ETV 0.5 mg capsule
Description: Brown capsules, each capsule containing 0.53 mg of entecavir hydrate
Study NCT05053477 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mehylprednisolone injection
Description: (40 mg)
Study NCT05053477 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: pulsed radiofrequency (PRF)
Description: . PRF lesion will be carried out for 120 seconds at a 2 Hz frequency and pulse width of 20 ms at 42°C
Study NCT05053477 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: platelet-rich plasma
Description: 2 ml of PRP
Study NCT04236648 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Minimally-invasive non-surgical therapy (MINST)
Description: subgingival root debridement with a minimally-invasive approach using piezoelectric/ultrasonic instruments
Study NCT01383096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OZ439 mesylate 800mg Powder in Bottle for Oral Suspension
Description: OZ439 800 mg (as free base) as powder in a bottle for reconstitution in a suspension prior to oral administration
Study NCT01383096 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OZ439 mesylate 800mg Powder in Bottle for Oral Suspension
Description: OZ439 800 mg (as free base) as powder in a bottle for reconstitution in a suspension prior to oral administration
Study NCT01383096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OZ439 mesylate 400mg Prototype Solution Formula 1
Description: OZ439 400 mg (as free base) as a prototype solution formulation 1
Study NCT01383096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OZ439 mesylate 800mg Prototype Solution Formula 1
Description: OZ439 800 mg (as free base) as a prototype solution formulation 1
Study NCT01383096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OZ439 mesylate 800mg Prototype Solution Formula 2
Description: OZ439 800 mg (as free base) as a prototype solution formulation 2
Study NCT00820976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: Filgrastim(5 µg/kg intravenously over 30 minutes ) was administered starting from day 8 until neutrophil recovery
Study NCT02869555 — intervention group
Intervention type: OTHER
Intervention: Data collection
Study NCT03025399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tangwang prescription
Description: A kind of Granule(Tangwang prescription) was composition by five Chinese herbal medicines, every bag has 4.87g granules.
Study NCT03025399 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is a simulated drug of tangwang prescription,included weight, appearance, colour, taste,smell and solubility.
Study NCT02243098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: Administered as a subcutaneous injection (s.c., under the skin). Initiated with weekly semaglutide dosing of 0.25 mg in the first 4 weeks, 0.5 mg the next 4 weeks, and 1.0 mg in the third 4 week period.
Study NCT02243098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: digoxin
Description: Oral administration. Digoxin will be given as 2 single doses of 0.5 mg.
Study NCT02243098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atorvastatin
Description: Oral administration. Atorvastatin will be given as 2 single doses of 40 mg.
Study NCT00987688 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypothermia
Description: exposure: Early and sustained hypothermia. Hypothermia will initially be induced by infusion of up to 2L ice cold saline. Following a safety assessment the patient will be rapidly cooled to 33C using surface temperature control equipment. They will be maintained at 33C for 72 hours. Rewarming will occur at a rate of 1C/4hrs and will be titrated to intracranial pressure (ICP) control and BP.
Study NCT01762670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GoldenCare
Description: Copper intravaginal device to treat bacterial vaginosis.
Study NCT01762670 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole
Description: 500 mg twice daily for 7 days
Study NCT02275585 — intervention group
Intervention type: OTHER
Intervention: Event of portal vein thrombosis
Description: There is no intervention over patients. They are followed during 3 years to look after any event of portal vein thrombosis